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Introduction
During evolution, multicellular organisms have devel  oped 
an impressive arsenal of defense and repair mechanisms to 
counteract threats such as infection and trauma. Such an 
inﬂ  ammatory response begins with the detection of the 
potential life-threatening event by recognizing so-called 
danger signals. Th  ese signal molecules have been classi-
cally divided into: i) Exogenous, pathogen-associated 
molecular patterns (PAMPs) [1], which are con  served 
motifs on pathogens that are not found in higher eukaryo-
cytes; and ii) endogenous innate danger mole  cules, also 
named damage-associated molecular patterns (DAMPs) 
or alarmins, which are structurally diverse proteins rapidly 
released by the host itself during infec  tion or (sterile) 
tissue damage [2].
Known PAMPs include lipopolysaccharide (LPS) from 
the outer membrane of Gram-negative bacteria, peptido-
glycan (present in most bacteria), lipoteichoic acid (in 
many Gram-positive bacteria), bacterial DNA, viral 
DNA/RNA and mannans in the yeast cell wall. PAMPs 
are recognized by pattern recognition receptors (PRRs), 
in particular Toll-like receptors (TLRs) and Nod-like 
receptors (NLRs), leading to an inﬂ  ammatory response 
via several signaling pathways, including nuclear factor-
kappa B (NF-κB) activation and subsequent tumor 
necrosis factor (TNF)-α production.
Examples of putative DAMPs, the endogenous equiva-
lents of PAMPs, are high-mobility group box 1 (HMGB1), 
some S100 proteins (S100A8/A9, S100A12), interleukins 
such as IL-1α, heat-shock proteins (HSPs), and nucleo-
somes [3]. DAMPs can be secreted either actively or 
passively following necrosis but are not released by 
apoptotic cells [4] and have activating eﬀ  ects on receptor-
expressing cells engaged in host defense. DAMPs can also 
be detected by TLRs and NLRs and their engagement 
induces NF-κB activation as well, suggesting that DAMPs 
and PAMPs use, at least partially, the same receptors and 
signaling pathways. Liu et al. [5] however, propose that the 
immune system treats DAMPs and PAMPs diﬀ  erently; 
they suggest that DAMPs – but not PAMPs – bring CD24-
Siglec G/10 into the proximity of TLRs/NLRs, resulting in 
repressed DAMP-induced TLR/NLR signaling.
When invaded by pathogens, host defense systems 
encounter PAMPs from microorganisms and DAMPs 
that are released from tissues, which are recognized by 
TLRs and NLRs to warn the host of imminent danger. In 
addition, the multiligand receptor for advanced glycation 
endproducts (RAGE) is regarded as a prototypic DAMP 
receptor that can bind several DAMPs, including 
HMGB1 and S100A12 [6]. Other known RAGE ligands 
include amyloid, β-sheet ﬁ   brils, S100B and S100P [7]; 
furthermore, β2 integrins can interact with RAGE [8]. 
RAGE is expressed at high levels in the lungs and at low 
levels in normal adult tissues, including on cells involved 
in the innate immune system, e.g., neutrophils, T and B 
lymphocytes, monocytes, macrophages, dendritic cells, 
and endothelial cells [7]. Engagement of RAGE by its 
ligands leads to receptor-dependent signaling and 
activation of NF-κB and mitogen-activated protein kinase 
(MAPK) pathways [7]. Activation of RAGE plays a role in 
diverse experimentally-induced sterile inﬂ  ammatory and 
infectious diseases, including cecal ligation and puncture 
(CLP)-induced abdominal sepsis [9], diabetic nephro-
pathy, delayed type hypersensitivity, type II collagen 
induced arthritis, hepatic injury, and diabetic athero-
sclerosis [7,10–12]. Th   is review focuses on new insights 
into the pathogenesis of infectious diseases, including 
sepsis, peritonitis and pneumonia, oﬀ   ered by studies 
conducted in the RAGE research ﬁ  eld.
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RAGE consists of three immunoglobulin-like regions, a 
transmembrane domain, and a highly charged short 
cytosolic tail that is essential for intracellular signaling 
[13]. Th   e V domain in the extracellular part of RAGE is 
essential for binding of its ligands. Because of its ability to 
recognize three-dimensional structures rather than 
speciﬁ  c amino acid sequences, RAGE can interact with a 
wide range of ligands. RAGE was ﬁ  rst  identiﬁ   ed as a 
receptor for advanced glycation endproducts (AGEs), 
explaining its name. AGEs are products of the non-
enzymatic glycation and oxidation of lipids, proteins and 
other macromolecules that appear, in particular, under 
conditions of increased availability of reducing sugars 
and/or enhanced oxidative stress, especially when 
molecules turn over slowly and aldose levels are elevated. 
Further investigations showed that RAGE can recognize 
a diverse array of endogenous molecules that warn the 
immune system and induce a defensive immune 
response; the alarmins or DAMPs.
Putative RAGE ligands in infectious diseases
HMGB1
HMGB1 is a non-histone DNA-binding protein that 
serves as a structural component to facilitate the assembly 
of nucleoprotein complexes in the nucleus [14]. Extra-
cellularly, HMGB1 functions as a cytokine. In response to 
inﬂ  ammatory stimuli, including PAMPs, HMGB1 can be 
actively released into the extracellular environment from 
a variety of cells including monocytes, macrophages, 
endothelial cells, enterocytes, pituicytes, dendritic cells, 
and natural killer cells [14]. HMGB1 can also be passively 
secreted into the extracellular milieu when cells die in a 
non-programmed way (necrosis), whereas apoptotic cells 
modify their chromatin so that HMGB1 binds irreversibly 
and consequently is not released [4]. During infectious 
diseases, increased HMGB1 concentrations may be due 
to active as well as passive release. Detection methods of 
HMGB1 that are currently used (and published) do not 
distinguish between these (and possible other) diﬀ  erent 
forms of HMGB1. More studies are necessary to: 1) 
Report the biological activity of (diﬀ   erent forms of) 
HMGB1; and 2) develop HMGB1 ELISA assays that can 
distinguish between these (possibly also functionally) 
diﬀ   erent forms of HMGB1. Most investigations on 
HMGB1 and infection involve sepsis, the second leading 
cause of death in non-coronary intensive care units 
(ICUs) and the 10th leading cause of death overall. 
Patients with severe sepsis display elevated circulating 
HMGB1 levels [15–17] and HMGB1 is predominantly 
released at the site of infection; patients with pneumonia 
and those with peritonitis showed increased concen  tra-
tions in ﬂ  uid obtained from the bronchoalveolar space 
and abdomen, respectively [17]. In an animal model of 
CLP-induced sepsis, the kinetics of HMGB1 secretion in 
vivo  was delayed and more sustained when compared 
with the release of pro-inﬂ   ammatory cytokines, like 
TNF-α, IL-1β and IL-6 [18,19]. Similarly, various inter-
ventions that inhibit HMGB1 activity or production, such 
as anti-HMGB1 antibodies, the A-box segment of 
HMGB1, ethyl pyruvate, and nicotine, reduced CLP-
induced sepsis and/or LPS lethality even if treatment was 
delayed for many hours, up to one day after the challenge 
[20,21]. An implicated crucial event in sepsis patho-
physio  logy is apoptosis of immune cells, playing a major 
role in immunosuppression and lethality [22]. HMGB1 
seems to be a downstream factor of apoptosis in the ﬁ  nal 
common pathway to organ damage in severe sepsis as 
indicated by observations that prevention of lymphocyte 
apoptosis improved survival after CLP [23], whereas anti-
HMGB1 treatment reduced lethality in the same model 
without inﬂ   uencing apoptosis [19]. Th  is indicates that 
HMGB1 secretion is a relatively late event in sepsis that 
contributes signiﬁ   cantly to a worsened outcome. In 
addition, it has been reported that very pure HMGB1 
does not have cytokine-inducing capacity itself, but acti-
vates cells indirectly by ﬁ  rst acquiring immune stimu-
lating CpG DNA [24], which is released in the blood-
stream during bacterial sepsis. However, a recent study 
reported that HMGB1-mediated induction of macro-
phage cytokine production requires binding to TLR4, 
and that binding and signaling are dependent on a 
molecular mechanism that requires cysteine in position 
106 within the B box [25]. Together these data indicate 
that HMGB1 may exert pro-inﬂ  ammatory  eﬀ  ects in a 
direct TLR4-dependent way and an indirect way via 
binding of DAMPs and other agonistic molecules.
S100A12
S100A12 is a calcium binding protein expressed in the 
cytoplasm of neutrophils, where it comprises 5% of the 
total protein content. Furthermore, S100A12 – also 
known as EN-RAGE (extracellular newly identiﬁ  ed ligand 
of RAGE) or myeloid-related protein (MRP)-6 – is found 
in monocytes and lymphocytes and provokes pro-in-
ﬂ  ammatory responses in endothelial cells [26]. Although 
many RAGE ligands are promiscuous with regard to 
receptor use, S100A12 has only been shown to bind to 
RAGE. S100A12 expression is high in inﬂ  ammatory 
diseases such as atherosclerosis, rheumatoid arthritis, 
Crohn’s disease, Kawaski disease, and cystic ﬁ  brosis. 
Within the lungs, S100A12 and RAGE are increased 
during acute lung injury (ALI) [26]. S100A12 expression 
may reﬂ  ect activation of neutrophils during pulmonary 
inﬂ   ammation and may contribute to endothelial 
activation via binding to RAGE [26].
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Recruitment of leukocytes to the site of infection is an 
essential step in host defense during infectious diseases 
against invading pathogens. RAGE plays a role in the 
regulation of cell migration in several ways. First of all, 
RAGE is a counter-receptor for integrins on leukocytes; 
in particular, RAGE has been identiﬁ   ed as a binding 
partner for the β2 integrins, Mac-1 and p150, 95 [8]. 
Second, by the interaction of RAGE with β2 integrin-
mediated leukocyte recruitment in vivo: RAGE-/- mice 
displayed a diminished number of adherent inﬂ  ammatory 
cells on the peritoneum after CLP [9] and a reduction in 
neutrophil inﬂ   ux in the peritoneal cavity after 
thioglycollate peritonitis [8]. Interestingly, HMGB1 can 
activate lateral (in cis) RAGE-Mac-1 interactions on the 
leukocyte cell surface, enhancing Mac-1-intercellular 
adhesion molecule (ICAM)-1-dependent adhesion and 
migration [27] (Fig. 1, indicated by the blue line and blue 
“+”). Furthermore, a recent report shows that endothelial 
expressed RAGE acts in concert with ICAM-1 in 
mediating β2 integrin-dependent leukocyte adhesion 
during acute trauma-induced inﬂ  ammation [28] (Fig. 1, 
indicated by the green line and green “+”).
RAGE: a signal transducing receptor
Th  e signaling cascade(s) of RAGE – induced by engage-
ment of its various ligands – that ultimately activates 
NF-κB is largely unknown. Th   e predicted cytosolic portion 
of RAGE, consisting of 43 amino acids, is short compared 
to other PRRs, the TLRs and IL-1 receptors, and does not 
include a known signaling domain or motif. A RAGE 
mutant lacking this intracellular tail does not activate NF-
κB and behaves like a dominant negative, preventing pro-
inﬂ  ammatory cytokine release from macro  phages. Th  ese 
data indicate a critical role of this cytosolic portion in 
transducing the signal from the cell surface to the nucleus. 
Figure 1. Putative involvement of the receptor for advanced glycation endproducts (RAGE) during infection. The damage-associated 
molecular patterns (DAMPs), high-mobility group box 1 (HMGB1) and S100A12, are released during infection ([15, 17], and unpublished data) and 
bind to and activate RAGE. It has to be determined whether other S100 proteins and other DAMPs are RAGE ligands (indicated as purple shapes) 
released during infection. It would be interesting to investigate whether RAGE can directly bind to, become activated and mount a fi  rst immune 
reaction after ligation with specifi  c PAMPs as well. Engagement of RAGE by its ligands results in receptor-dependent signaling and activation of NF-
κB leading to a pro-infl  ammatory response; the signaling pathway is largely unknown. In addition, RAGE interacts as an endothelial (and epithelial) 
adhesion receptor with the leukocyte integrin, CD11b/CD18 (Mac-1) (lower section) [8]. Furthermore, lateral (in cis) RAGE-Mac-1 interaction on the 
leukocyte surface is mediated by HMGB1 and activates Mac-1-intercellular adhesion molecule (ICAM)-1 dependent adhesion and migration and 
augments leukocyte recruitment [27] (indicated by the blue line and blue „+“). Moreover, a recent report shows that endothelially expressed RAGE 
acts in concert with ICAM-1 in mediating β2 integrin–dependent leukocyte adhesion during acute trauma–induced infl  ammation [28] (indicated by 
the green line and green „+“).
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framing a whole `new’ signaling cascade to NF-κB. 
Another possibility is that the RAGE tail interacts with a 
Toll/IL-1 receptor (TIR)-containing protein which then 
recruits the downstream TIR-contain  ing proteins in a way 
analogous to TLR-mediated signaling pathways. Finally, 
RAGE could transduce signals from the cell surface to the 
nucleus by bypassing the TIR-containing adaptor, directly 
interacting with member(s) of the signaling cascade.
In addition to triggering NF-κB activation, RAGE 
engage  ment by its myriad ligands is linked to an array of 
signaling pathways, including MAPK family members, 
such as Jun-N-terminal kinase (JNK), p38 and extra-
cellular signal-regulated kinase (ERK), PI3K/Akt, Rho 
GTPases, Jak/STAT and Src family kinases [7].
Th  is rather extraordinary variety of observed signals 
may be due to the broad expression of RAGE, its diversity 
of ligands, and possible contaminating elements in the 
preparations used in experiments.
Soluble RAGE (sRAGE)
Th   e truncated form of full-length RAGE, soluble RAGE 
(sRAGE), consists of only the extracellular ligand-binding 
domain (V-C-C’) lacking the cytosolic and trans  mem-
brane domains (i.e., the parts that transfer a signal into 
the cell) and circulates in the bloodstream. sRAGE has 
been indicated to be involved in inﬂ  ammatory processes 
in several ways. First, sRAGE blood concentrations are 
associated with various inﬂ  ammatory diseases in patients 
and in rats with experimentally induced ALI [29]. 
Further  more, it is suggested that sRAGE can compete 
with full length cell-surface RAGE for ligand engagement, 
preventing these ligands from binding to RAGE or other 
receptors and/or exerting eﬀ  ects otherwise. Exogenous 
sRAGE treatment indeed attenuated inﬂ  ammatory res-
ponses in several animal models, including models of 
type II collagen-induced arthritis, hepatic injury, diabetic 
atherosclerosis, delayed type hypersensitivity, and experi-
mental auto-immune encephalomyelitis [7]. Th  e involve-
ment of sRAGE during infection is not known. Based on 
experimental studies in rats and in patients with ALI, 
sRAGE has been described as a marker of lung injury [29].
RAGE during infection
An increasing amount of research suggests a role for 
RAGE in the pathogenesis of pneumonia, peritonitis and 
sepsis, indicating that RAGE (ligand)-directed therapies 
might oﬀ   er new treatment opportunities for human 
disease in the future.
RAGE during pneumonia
Localization and role of RAGE in the lungs
Recent studies point to an important role of RAGE in the 
pulmonary compartment in physiological as well as in 
pathological circumstances. Physiologically, RAGE is 
expressed at high basal levels in the lungs relative to 
other tissues [26,29–34], suggesting that RAGE may have 
lung-speciﬁ  c functions distinct from the role of RAGE in 
other adult tissues. In particular, although the kidney is 
dramatically aﬀ  ected by microangiopathy and ﬁ  brosis – 
which is substantially attributed to RAGE – in patients 
with diabetes, the lungs, with a signiﬁ  cantly  higher 
baseline RAGE expression than the kidney, remain 
unaﬀ   ected. In addition, RAGE has been found to be 
speciﬁ  cally localized near the basal cell membrane within 
alveolar pneumocytes [32,35,36]. Th   ese two observa  tions 
raise the question as to whether RAGE has a function in 
normal healthy lungs. Indeed, Englert et al. documented 
that aged RAGE-/- mice develop pulmonary ﬁ  brosis-like 
alterations spontaneously; lungs from 19 to 24 month-old 
RAGE-/- mice showed increased collagen staining and 
displayed increased levels of hydroxyproline relative to 
wild type mice [31]. RAGE knockdown in pulmonary 
ﬁ  broblasts increased their proliferation and migration in 
vitro, suggesting an important protective function of 
RAGE in the lungs and that loss of RAGE may be related 
to functional changes of pulmonary cell types resulting in 
ﬁ  brotic disease [34]. Another study demonstrated that 
RAGE on epithelial cells promoted their adherence to 
human collagen (a major component of the alveolar basal 
lamina) and a spreading morphology, which may facilitate 
gas exchange and alveolar stability in vivo [34,35]. 
Together, these data suggest that RAGE plays a role in 
maintaining lung homeostasis in normal, healthy lungs. 
Further studies are needed to unravel the function(s) of 
pulmonary RAGE in physiology in more detail.
Th   is putative functional role of RAGE in healthy lungs 
may be the explanation for the ﬁ  nding that the inhibition 
of RAGE signaling attenuates pathological sterile inﬂ  am-
matory responses in diverse non-pulmonary experi  men-
tal studies [9–12], whereas in pulmonary non-infectious 
pathological inﬂ   ammatory conditions, somewhat con-
ﬂ   ict  ing results emerge. Lung injury induced by either 
bleomycin or hyperoxia is diminished in RAGE-/- mice 
[37,38], suggesting a deteriorating attribution of RAGE. 
In contrast, Englert et al. showed that RAGE-/- mice 
developed more severe lung ﬁ   brosis after asbestos 
adminis  tration as measured by histological scoring and 
total lung hydroxyproline quantiﬁ  cation [31]. Of note, in 
all these studies, the mice were much younger at the time 
of sacriﬁ   ce than the aged (19–24 month-old) RAGE-/- 
mice that developed pulmonary ﬁ  brosis spontaneously in 
the experiment by Englert et al. [31]. Interestingly, lung 
homogenates and bronchoalveolar lavage (BAL) ﬂ  uid 
from patients suﬀ   ering from idiopathic pulmonary 
ﬁ  brosis reveal reduced membrane bound (and soluble) 
RAGE protein levels compared to healthy donor samples 
[31,34].
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Community-acquired pneumonia (CAP) is distinguished 
from hospital-acquired pneumonia (HAP) according to 
the time of acquisition of pneumonia and the pathogens 
involved. Th  e Gram-positive bacterium, Streptococcus 
pneumoniae, is the single most frequent pathogen 
causing CAP, responsible for up to 60% of cases; Kleb-
siella pneumoniae,  Haemophilus inﬂ  uenzae,  Staphylo-
coccus aureus, and viruses are isolated in about 10% of 
cases each and Mycobacterium  tuberculosis is more 
prevalent in developing countries. Knowledge of the 
expression and role of RAGE in host defense during 
pneumonia is limited. Morbini et al. observed increased 
RAGE expression in patients with interstitial and post-
obstructive pneumonia [32]; this report left unanswered 
whether patients with bacterial pneumonia were included 
in the analysis. Notably, two other studies showed that 
constitutively present RAGE was not upregulated during 
pulmonary inﬂ  ammation associated with ALI or acute 
respiratory distress syndrome (ARDS): First, rats with 
ALI induced by intratracheally administered LPS 
displayed no change in the distribution of RAGE-
expressing cells [29]; and second, patients with ARDS did 
not have increased pulmonary expression of RAGE [26].
sRAGE has been suggested to be a lung injury marker 
based on studies in patients with ALI and on experi-
mental studies in rats [29]. sRAGE was increased in 
pulmonary edema ﬂ  uid and serum from patients with 
either ALI or ARDS and with hydrostatic pulmonary 
edema, and in BAL ﬂ  uid from rats with either LPS- or 
hydro  chloric acid-induced ALI [29].
Considering the ubiquitous expression of RAGE in the 
lungs, its putative involvement in the regulation of lung 
inﬂ   ammation and the somewhat inconsistent ﬁ  ndings 
which currently exist in the literature, we investigated its 
role during pneumonia, a major cause of morbidity and 
mortality world-wide. Recently, we reported that murine 
pneumonia induced by S. pneumoniae and by inﬂ  uenza A 
virus was associated with an upregulation of intra-
alveolar (membrane bound) RAGE expression [39,40]. 
Furthermore, lung tissue of mice intranasally infected 
with the K. pneumoniae or with M. tuberculosis also 
showed increased RAGE expression (unpublished data). 
Th   ese clinically very diﬀ  erent types of pulmonary infec-
tion and the involvement of RAGE therein will be 
discussed below.
Role of RAGE in pneumonia caused by diff  erent pathogens
Levels of the high-aﬃ   nity RAGE ligand, HMGB1, were 
higher in BAL ﬂ   uid from patients with pneumonia 
compared to BAL ﬂ  uid from healthy controls [17]. In 
experimentally induced pneumococcal pneumonia, the 
presence of RAGE was detrimental: Mice lacking RAGE 
had a better survival rate together with a lower 
pulmonary bacterial load and decreased dissemination of 
S. pneumoniae to blood and spleen compared to wild-
type mice [39]. Th  e  diﬀ  erence was possibly partially due 
to an increased killing capacity of RAGE-/- alveolar 
macrophages. Additionally, lung injury and neutrophil 
recruitment were reduced in the RAGE-/- mice, which 
parallels ﬁ   ndings on RAGE as an endothelial counter 
receptor for the β2 integrin, Mac-1, [8] and the interplay 
between RAGE and Mac-1 on leukocytes, required for 
HMGB1-mediated inﬂ  ammatory cell recruitment [27]. In 
addition, blockade of the RAGE-HMGB1 interaction and 
prevention of the subsequent pro-inﬂ  ammatory stimulus 
might be an explanation for the less severe pulmonary 
damage in the RAGE-/- mice during S. pneumoniae 
pneumonia.
Interestingly, in contrast to Gram-positive pneumonia, 
preliminary data from our laboratory reveal that RAGE 
plays a beneﬁ  cial role in mice during the host response to 
Gram-negative pneumonia (unpublished data). Indeed, 
RAGE deﬁ  ciency was associated with increased mortality 
and increased bacterial outgrowth and dissemination 
after  K. pneumoniae inoculation (unpublished data). 
Relative to wild type mice, lung inﬂ  ammation was similar 
and cytokine and chemokine levels were slightly – if at all – 
elevated. Moreover, RAGE-/- mice showed an unaltered 
response to intranasally instilled Klebsiella LPS with 
respect to pulmonary cell recruitment and local release 
of cytokines and chemokines. Together, these ﬁ  ndings 
indicate that RAGE contributes to an eﬀ  ective  anti-
bacterial host response during K. pneumoniae pneu-
monia, whereas RAGE plays an insigniﬁ  cant part in the 
lung inﬂ  ammatory response to either intact Klebsiella or 
Klebsiella LPS.
It is unclear whether RAGE can also interact with 
ligands from pathogens. If so, this could be part of the 
explanation for our observation that RAGE involvement 
during Gram-positive and –negative pneumonia had 
such opposite eﬀ  ects on mortality. In addition, RAGE-
mediated eﬀ  ects on other ﬁ  rst-line defense mechanisms, 
such as chemotaxis, phagocytosis, killing (including 
respiratory burst), may depend on the pathogen and may 
contribute to the observed eﬀ  ects in Gram-positive and 
-negative pneumonia models. However, this remains 
speculative until investigations have been performed to 
analyze this interesting issue.
In addition to its potential to cause pandemics, 
seasonal inﬂ  uenza A virus infection causes over 200,000 
hospitalizations and approximately 41,000 deaths in the 
United States annually, being the 7th leading cause of 
mortality. We demonstrated that RAGE deﬁ  ciency 
resulted in a better outcome from pulmonary inﬂ  uenza A 
virus infection as indicated by a relative protection from 
inﬂ  uenza A virus-induced lethality in mice [40]. Th  is  was 
accompanied by improved viral clearance and enhanced 
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suggesting that endogenous RAGE impairs the cellular 
immunity against respiratory tract infection with inﬂ  u-
enza A virus. RAGE ligand, HMGB1, as well as sRAGE 
were upregulated in BAL ﬂ  uid during inﬂ  uenza A virus 
pneumonia. Hence, similar to pneumonia induced by the 
Gram-positive bacterium S. pneumoniae, RAGE is detri-
mental during pneumonia caused by inﬂ  uenza A virus. 
Th   is is of particular interest, since it has been suggested 
that the greatest proportion of the mortality associated 
with inﬂ   uenza A virus infection is due to secondary 
bacterial pneumonia, with S. pneumoniae as the most 
frequent pathogen of the superinfection. Th  erefore, 
RAGE is a potential treatment target in postinﬂ  uenza 
pneumococcal pneumonia and further research is 
warranted to investigate this.
RAGE during abdominal sepsis
Th   e role of RAGE in abdominal sepsis has been investi-
gated in a limited number of studies so far. RAGE-
deﬁ  cient mice showed decreased mortality after induc-
tion of polymicrobial sepsis induced by CLP in two 
reports [9,41]. Moreover, anti-RAGE antibody yielded a 
better survival even when the anti-RAGE therapy was 
delayed up to 24 hours after CLP in mice receiving 
antibiotics [41]. Th  e protective eﬀ   ect provided by the 
absence of RAGE was related to a ﬁ  rm  inhibition  of 
NF-κB activation, suggesting that the lack of excessive 
NF-κB activation in RAGE-/- mice might have contributed 
to their reduced mortality [9]. In addition, RAGE 
deﬁ   ciency resulted in fewer inﬂ   ammatory cells in the 
peritoneum [9], which parallels the results of an earlier 
investigation by the same group of authors identifying 
RAGE as a counter-receptor for the β2 integrin, Mac-1 
(CD11b/CD18), and thereby as a mediator of leukocyte 
recruitment and adhesion [8]. Furthermore, the 
protective eﬀ  ect of RAGE inhibition in this CLP model 
could at least in part be the consequence of the inhibition 
of one of its ligands, HMGB1. Indeed, HMGB1 is 
secreted into the circulation after CLP and anti-HMGB1 
antibody led to increased survival after CLP-induced 
peritonitis [18].
In the same surgically (CLP)-induced model of sepsis, 
RAGE deﬁ  ciency and anti-RAGE therapy were reported 
not to aﬀ  ect bacterial outgrowth in the peritoneum, liver, 
or spleen [41]. Notwithstanding, a possible role of RAGE 
in antibacterial defense cannot be easily evaluated from 
this study because host defense against CLP depends, at 
least in part, on the extent of intestinal necrosis and the 
formation of a local abscess. Also, all mice in this 
experiment received broad spectrum antibiotics and 
bacterial outgrowth was only determined in mice that 
survived (i.e., not at predeﬁ  ned time points after CLP). 
For this reason, we used our model of abdominal sepsis 
induced by injection of the Gram-negative bacterium 
Escherichia coli into the peritoneum [42,43] to study 
whether RAGE aﬀ  ects antibacterial defense. Th  is  model 
is a relevant tool to investigate the role of receptors/
mediators in limiting the growth and dissemination of 
bacteria after a primary intra-abdominal infection and to 
assess the contribution of these proteins to speciﬁ  c 
immune responses. RAGE expression was upregulated 
during  E. coli induced sepsis [42]. RAGE deﬁ  ciency 
(either pharmacologically using anti-RAGE IgG anti-
bodies or genetically using RAGE knock out mice) was 
related to a higher bacterial load and dissemination [42]. 
Th  ese data indicate that RAGE signaling contributes to 
an eﬀ   ective antibacterial response during abdominal 
sepsis. RAGE exerted this eﬀ  ect probably indirectly and 
not via direct interaction with E. coli, considering the 
observation that leukocytes from RAGE-/- mice had an 
unaltered capacity to phagocytose and kill E. coli in vitro. 
Furthermore, the ﬁ   nding that deﬁ   ciency of RAGE in 
general was associated with an exaggerated host response 
during E. coli sepsis [42] on the one hand, and with an 
attenuated inﬂ  ammatory response and better survival in 
(other) sterile models of intraperitoneal injection of LPS 
derived from E. coli [42,44] on the other hand, suggests 
that although RAGE is involved in the immune reaction 
to E. coli, this function can be compensated for by other 
receptors in the presence of a growing bacterial load. Th  e 
high-aﬃ   nity RAGE ligand, HMGB1, is secreted into the 
circulation systemically during clinical sepsis [16–18] as 
well as in our experimental sepsis model of E. coli [43]. 
Importantly, HMGB1 has been shown to transduce 
cellular signals in vitro and in vivo by interacting with at 
least three other receptors, i.e., TLR2, TLR4 and TLR9 
when HMGB1 is complexed with CPG DNA [24,44,45]. 
One possible explanation for the increased response in 
the RAGE lacking mice during E. coli sepsis is, therefore, 
that the absence of RAGE could facilitate the interaction 
between HMGB1 and TLR2, TLR4 and/or TLR9.
Evidence of involvement of ligands of RAGE and 
HMGB1 in host defense in E. coli abdominal sepsis was 
recently published by our laboratory [43]. Inhibition of 
multiple RAGE ligands (by the administration of sRAGE) 
and inhibition of HMGB1 (by the administration of anti-
HMGB1 antibodies) led to an enhanced bacterial 
dissemi nation  of  E. coli, denoting an advantageous role of 
RAGE ligands, including HMGB1, in the antibacterial 
response during Gram-negative sepsis.
Interestingly, we recently found that S100A12, another 
high-aﬃ   nity ligand of RAGE, is released systemically in 
patients during (abdominal) sepsis and also locally during 
peritonitis (unpublished data). Additionally, intravenous 
injection of LPS in healthy humans raised circulating 
S100A12 levels, implying that LPS might partially contri-
bute to this upregulation during Gram-negative infection. 
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mRNA S100A12 expression by circulating leukocytes 
was decreased during the recovery phase [46]. One 
possible function of S100A12 in host defense during 
infection and sepsis is its role as a DAMP. NF-κB 
mediated expression of pro-inﬂ  ammatory cytokines and 
upregulation of ICAM-1 and vascular cell adhesion 
molecule (VCAM)-1 on endothelium has been docu-
men ted  in vitro after S100A12 stimulation [47]. Further-
more, S100A12 could be of beneﬁ  t for the host during 
infection and sepsis due to its (more direct) antibacterial 
activity. Cole et al. determined that S100A12 has activity 
primarily against Gram-negative bacteria, including 
E.  coli [48]. Because of the absence of S100A12 in 
rodents, a potential functional role of S100A12 during 
sepsis cannot be easily investigated by inhibiting/deleting 
S100A12 in animals. Altogether, the role of S100A12 
during sepsis has yet to be evaluated using non-rodent 
models.
Bopp et al. documented that septic patients have 
elevated circulating sRAGE levels and that non-survivors 
show higher plasma sRAGE concentrations than sur-
vivors, suggesting that sRAGE is related to severity and 
clinical outcome in sepsis [49]. Knowledge on the role of 
endogenous sRAGE in sepsis is scarce. Hudson et al. 
demonstrated that sRAGE levels might represent an early 
marker of microvascular dysfunction, a pheno  me  non 
also present in sepsis [50]. Furthermore, increased 
sRAGE concentrations in sepsis might represent the 
acute inﬂ  ammatory status as splice variants of RAGE or 
as split oﬀ   variants of the cell surface RAGE, the latter 
analogous to ICAM-1, another member of the immuno-
globulin superfamily, which is a marker of cellular 
damage during sepsis. Another possibility is that systemic 
sRAGE levels might be elevated in parallel with HMGB1/
S100A12 levels as a counter-system against HMGB1/
S100A12 elicited tissue eﬀ  ects. More research is needed 
to clarify the functional role of sRAGE in sepsis and its 
putative role as a new sepsis marker.
Conclusion
Th  e innate immune response is the ﬁ  rst line of defense 
against pathogens. Th  e experimental studies described 
herein provide further insight into the role of RAGE and 
its ligands in host defense during clinically important 
infections, which eventually may contribute to better 
therapies against speciﬁ  c pathogens. While interpreting 
the results from preclinical investigations, one has to 
keep in mind that a careful balance between the inﬂ  am-
ma  tory and anti-inﬂ  ammatory response is vital in order 
to survive or recover from a severe infection.
Th   e observation that lack of RAGE is of beneﬁ  t in one 
pneumonia model and detrimental in another, clearly 
adds to the notion that the way in which RAGE mediates 
host defense against diﬀ  erent pathogens relies on distinct 
mechanisms. It would be highly interesting to evaluate 
whether RAGE can directly bind to, become activated, 
and mount a ﬁ  rst immune reaction after ligation with 
speciﬁ   c PAMPs. Furthermore, RAGE-mediated eﬀ  ects 
on other ﬁ  rst-line defense mechanisms, such as chemo-
taxis, killing, phagocytosis and respiratory burst could 
depend on the pathogen. As such, targeting RAGE may 
be ineﬀ  ective or even harmful in some infectious condi-
tions. Th  erefore, more studies are necessary to justify 
clinical trials targeting RAGE in patients with severe 
infections. In this respect one could think of research on 
RAGE inhibition in pneumococcal and inﬂ  uenza A viral 
pneumonia. Additionally, experiments in which RAGE 
targeting is delayed until after bacterial/viral infection 
and combined with antibiotic/antiviral therapy should be 
considered. Moreover, more studies need to be 
conducted on the role of RAGE in critical organ 
derangements involved in the pathogenesis of severe 
infection, including activation of the coagulation system 
and the complement system. RAGE remains a potential 
yet promising therapeutic target that awaits further 
research.
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